Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

AHA Updates Advice for Resuscitation, CV Care After Overdose or Poisons

L.A. McKeown

September 20, 2023

News Daily News

Career Flexibility Benefits Cardiologists, Patients Alike: ACC Report

Caitlin E. Cox

October 13, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

Todd Neale

January 29, 2019

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

Caitlin E. Cox

June 01, 2018

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Todd Neale

May 04, 2018

News Conference News ACC 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

Shelley Wood

March 27, 2018

News Daily News

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

Todd Neale

December 04, 2017

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News Stories for 2015

Shelley Wood

December 29, 2015

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

Shelley Wood

December 29, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

Advertisement

AHA Updates Advice for Resuscitation, CV Care After Overdose or Poisons

Career Flexibility Benefits Cardiologists, Patients Alike: ACC Report

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

The Biggest News of 2018: TCTMD’s Top 10

TCTMD’s Top 10 Most Popular Stories for May 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

ACC Provides Guidance on How to Manage Bleeding in Patients Taking Oral Anticoagulants

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

TCTMD’s Top 10 Most Popular News Stories for 2015

Las 10 Noticias de TCTMD Más Leídas de 2015

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content